Eckert & Ziegler BEBIG, Mick Radio-Nuclear Instruments, WOLF-Medizintechnik (WOmed)


Wir halten Sie auf dem Laufenden! Wenn Sie Fragen zu unseren Pressemitteilungen haben, können Sie uns gerne über das Kontaktformular der Website kontaktieren. Bleiben Sie über die neuesten Nachrichten unseres Unternehmens auf dem Laufenden:

Eckert & Ziegler BEBIG announces first SagiNova® brachytherapy afterloader in the U.S.

Oxford, Connecticut, USA, December 14, 2015, Eckert & Ziegler BEBIG, Inc. is pleased to announce the first placement of its new SagiNova® High Dose Rate afterloader system in the United States at Peninsula Regional Medical Center in Salisbury, Maryland. This accomplishment is significant as the United States represents the largest single country market in the world for brachytherapy.

SagiNova® HDR afterloader

The Peninsula Regional Medical Center focuses on the treatment of endometrial cancer, cervix cancer, and breast cancer. The Peninsula Regional's Richard A. Henson Cancer Institute has almost a 30 year record of experience in HDR brachytherapy and continuously expands its treatment offerings.

Bill Dowd, Chief Executive Officer of Eckert & Ziegler BEBIG, Inc. commented "We are proud to partner with the clinicians at Peninsula Regional Medical Center to bring the latest HDR brachytherapy treatment technology available to their patients."

Additionally, John Mansueti M.D. of Peninsula Regional Medical Center said "As Medical Director of Radiation Oncology, I am excited to announce our collaboration with Eckert & Ziegler BEBIG to introduce the SagiNova® HDR afterloader to the U.S. market.  We were extremely impressed with the advanced technology and safety features incorporated into their HDR system. Their vast brachytherapy experience made the decision quite easy for our physicians."

About High Dose Rate (HDR) Brachytherapy
HDR brachytherapy allows radiation oncologists to deliver the radiation quickly, mostly as an outpatient procedure. During this procedure a computer driven apparatus, called a remote afterloading device, pushes the radioactive source, which is attached to a wire, through the transfer tubes and the applicators to the treatment site. The radioactive source can be moved in millimeter increments and remain in a certain position (dwell position) for a predetermined amount of time. When the desired treatment dose has been achieved, the remote afterloading device automatically withdraws the radioactive source so there is no residual radiation or radioactivity.

HDR brachytherapy is used since the 1960s and today is applied to treat cancers in body sites such as the female reproductive system, rectum, prostate and breast. The procedure enables an accurate and precise tumor specific radiation dose delivery in a short course of treatment (compared to other types of radiation treatment) while preserving the structure and the function of the organ.

About Peninsula Regional Medical Center
Peninsula Regional Medical Center (PRMC) in Salisbury, Maryland, a subsidiary of the Peninsula Regional Health System, offers the widest array of specialty and subspecialty services on the Delmarva Peninsula.  At 292 hospital beds, PRMC has been meeting the healthcare needs of Delmarva Peninsula residents since 1897. Its 3,300 physicians, staff and volunteers provide safe, compassionate and affordable care designed to exceed the expectations of the nearly 500,000 patients who rely on the Medical Center team each year for inpatient, outpatient, diagnostic, subacute and emergency/trauma services.  It is the recipient of more than 125 national awards, recognitions and certifications in the past half-decade for the care it offers patients and the outcomes they experience. Peninsula Regional is also proud to be an affiliate of the Johns Hopkins Clinical Research Network (JHCRN), a group of academic and community-based clinical researchers designed to provide new opportunities for research collaborations.

About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treat­ment of cancer using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and in the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents, to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Eckert & Ziegler BEBIG employs approximately 150 people. The company has been listed on the Euronext stock exchange since April 1997.

Annica Witt
Marketing Communication Manager